Screener
Spyre Therapeutics, Inc. SYRE Debt-to-equity
Discontinued — last reported Q1 '23
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 9, 2024. Open the filing →
- Filed
- May 9, 2024
- Fiscal quarter
- Q1 FY2024
- Calendar quarter
- Q1 2024
- Accession
- 0001636282-24-000037
FAQ
- What is Spyre Therapeutics, Inc.'s debt-to-equity?
- Spyre Therapeutics, Inc. (SYRE) reported debt-to-equity of 0.1× in Q1 2023.
- How has Spyre Therapeutics, Inc.'s debt-to-equity changed year-over-year?
- Spyre Therapeutics, Inc.'s debt-to-equity increased by 64.8% year-over-year, from 0.1× to 0.1×.
- What is the long-term trend for Spyre Therapeutics, Inc.'s debt-to-equity?
- Over 2 years (2020 to 2022), Spyre Therapeutics, Inc.'s debt-to-equity has grown at a 52.9% compound annual growth rate (CAGR), from 0× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Spyre Therapeutics, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude